Tauvid™: The first FDA-approved pet tracer for imaging tau pathology in Alzheimer’s disease
dc.contributor.author
Jie, Caitlin V.M.L.
dc.contributor.author
Treyer, Valérie
dc.contributor.author
Schibli, Roger
dc.contributor.author
Mu, Linjing
dc.date.accessioned
2021-02-25T11:33:42Z
dc.date.available
2021-02-24T09:50:35Z
dc.date.available
2021-02-25T11:33:42Z
dc.date.issued
2021-02
dc.identifier.issn
1424-8247
dc.identifier.other
10.3390/ph14020110
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/471292
dc.identifier.doi
10.3929/ethz-b-000471292
dc.description.abstract
Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer’s disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the main pathologies present in AD and is receiving increasing attention as a diagnostic and therapeutic target. In this review, we summarised the production and quality control of Tauvid, its clinical application, pharmacology and pharmacokinetics, as well as its limitation due to off-target binding. Moreover, a brief overview on the second-generation of Tau PET tracers is provided. The approval of Tauvid marks a step forward in the field of AD research and opens up opportunities for second-generation tau tracers to advance tau PET imaging in the clinic.
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
MDPI
en_US
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
tauvid™
en_US
dc.subject
[18F]flortaucipir
en_US
dc.subject
alzheimer’s disease
en_US
dc.subject
tau neurofibrillary tangles (NFTs)
en_US
dc.subject
PET
en_US
dc.title
Tauvid™: The first FDA-approved pet tracer for imaging tau pathology in Alzheimer’s disease
en_US
dc.type
Review Article
dc.rights.license
Creative Commons Attribution 4.0 International
dc.date.published
2021-01-30
ethz.journal.title
Pharmaceuticals
ethz.journal.volume
14
en_US
ethz.journal.issue
2
en_US
ethz.pages.start
110
en_US
ethz.size
12 p.
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
Basel
en_US
ethz.publication.status
published
en_US
ethz.leitzahl
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02020 - Dep. Chemie und Angewandte Biowiss. / Dep. of Chemistry and Applied Biosc.::02534 - Institut für Pharmazeutische Wiss. / Institute of Pharmaceutical Sciences::03688 - Schibli, Roger / Schibli, Roger
ethz.leitzahl.certified
ETH Zürich::00002 - ETH Zürich::00012 - Lehre und Forschung::00007 - Departemente::02020 - Dep. Chemie und Angewandte Biowiss. / Dep. of Chemistry and Applied Biosc.::02534 - Institut für Pharmazeutische Wiss. / Institute of Pharmaceutical Sciences::03688 - Schibli, Roger / Schibli, Roger
ethz.date.deposited
2021-02-24T09:50:54Z
ethz.source
SCOPUS
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2021-02-25T11:33:53Z
ethz.rosetta.lastUpdated
2023-02-06T21:31:04Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Tauvid%E2%84%A2:%20The%20first%20FDA-approved%20pet%20tracer%20for%20imaging%20tau%20pathology%20in%20Alzheimer%E2%80%99s%20disease&rft.jtitle=Pharmaceuticals&rft.date=2021-02&rft.volume=14&rft.issue=2&rft.spage=110&rft.issn=1424-8247&rft.au=Jie,%20Caitlin%20V.M.L.&Treyer,%20Val%C3%A9rie&Schibli,%20Roger&Mu,%20Linjing&rft.genre=article&rft_id=info:doi/10.3390/ph14020110&
Files in this item
Publication type
-
Review Article [4048]